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Abstract Introduction of the so-called biocompatible perito-
neal dialysis (PD) fluids was based on a large body of exper-
imental evidence and various clinical trials suggesting impor-
tant clinical benefits. Of these, until now, only preservation of
residual renal function—likely due to lower glucose degrada-
tion product load and, in case of icodextrin, improved fluid
and blood pressure control—have consistently been proven,
whereas the impact on important clinical endpoints such as
infectious complications, preservation of PDmembrane trans-
port function, and patient outcome, are still debated. In view
of the high morbidity and mortality rates of PD patients, novel
approaches are warranted and comprise the search for alterna-
tive osmotic agents and enrichment of PD fluids with specific
pharmacologic agents, such as alanyl-glutamine, potentially
counteracting local but also systemic sequelae of uremia and
PD.
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Medical need: What happens to the patient on PD
in 2016?
Treatment with peritoneal dialysis (PD) allows home-based
renal replacement therapy (RRT) and thus better patient
integration into normal social life, such as school and other
aspects important for quality of life (QoL), even though im-
posing a major burden to families. In pediatric nephrology, PD
is the most frequently used dialysis modality until adolescence
[1]. More than 90 % of young children are treated with PD as
RRT within the first 2 years of life [2]. This is exactly the
opposite distribution to adult patients on dialysis, in whom
<10 % are treated by PD worldwide, despite improving out-
come [3].Whereas data onmorbidity andmortality comparing
different forms of dialysis in pediatrics are scarce, such data in
adults mostly show comparable outcome, depending on pop-
ulation selection and cultural and socioeconomic background
of the healthcare system in the countries in which the studies
where performed. Latest analyses of adult patients on RRT
even suggest a superior outcome of PD compared with hemo-
dialysis (HD) but a strikingly declining PD usage, at least in
Europe [3]. Moreover, studies in the adult population show
consistent advantages of PD with regard to QoL indices and
economic costs to healthcare providers [4, 5]. However, de-
spite technological progress allowing an acceptable QoL for
children waiting for renal transplantation [6], PD treatment is
still frequently hampered by infectious and noninfectious
complications. A recent large competitive risk analysis in al-
most 9,000 elderly patients, of whom 50% required assistance
at home, demonstrated that 25 % experienced at least one
episode of peritonitis within 1 year. Even without having ex-
perienced peritonitis, within 2 years, 11 % of PD patients
switched to HD, and >20 % of PD patients died [7]. The
individual impact of PD on mortality is difficult to interpret
due to the multimorbidity of these cohorts. In pediatrics, data
from [2] demonstrated that 20 % of children who were started
on PD within the first year of life and who had an array of
comorbid conditions died within the first 2 years of treatment,
mainly because of infections [2]. Overall, survival of pediatric
patients on PD is 94% at 5 years in countries with a per-capita
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gross national income above US $28,000 per year and 89% in
countries with lower income [8]. Thus, survival of children
with chronic renal failure who end on PD therapy is no better
than in children with common oncologic diagnoses [9].
Infectious complication and hospitalization rates declined
over the past 30 years in children on PD but are still two-
and three-fold higher than in children on HD and after kidney
transplantation, respectively [10]. The International Pediatric
Hemodialysis Network (IPHN; www.pedpd.org) has
monitored children on HD for 3 years and will allow
respective comparisons with children on PD. Taken together,
there is a highmedical need to improve the clinical outcome of
children who undergo PD. Current clinical and experimental
data suggest that the nonphysiological composition of PD
fluids plays a major role in putting the child at risk for
infectious and noninfectious complications. This review first
focuses on the current status of PD fluids then discusses
underlying pathomechanisms that put patients at risk for
peritoneal and systemic complications and, second, provides
a short summary and outlook on current research and
development to tackle these problems in order to improve
PD therapy.
Current PD solutions
The indication for PD fluids is replacement of renal func-
tion in acute and chronic renal failure, thus the removal of
water and solutes (including uremic toxins) from the ure-
mic patient. The therapeutic effects of these fluids are
achieved through their physicochemical composition,
i.e., ultrafiltration (UF) of water by the nonphysio log-
ically increased concentration of osmotical ly or
oncotically active agents (such as glucose, icodextrin or
amino acids, resulting in an osmolality of 284 mOsmol/l
with 7.5 % icodextrin to 511 mOsmol/l with 4.25 % glu-
cose) and low concentrations or absence of solutes that
should be removed (mostly intracellular ions, including
potassium and phosphate and multiple metabolic waste
products). Currently, registered single-chamber-bag
glucose-based PD fluids are CAPD®, Dianeal®, and
Gambrosol®, and the so-called biocompatible multi-
chamber-bag f lu ids a re BicaVera®, Balance®,
Gambrosol trio®, Physioneal®, and the non-glucose-
based fluids Nutrineal® and Extraneal® (details in [16].
Additional bioincompatibility of these fluids is introduced
by pharmaceutical production (e.g., with heat steriliza-
tion), resulting in glucose degradation products (GDP)
and adducts, but also by economic constraints (such as
absence of essential nutrients, as would be present in most
cel l cul ture media) . As a resul t , PD fluids are
bioincompatible (if not frankly cytotoxic), with different
profiles depending on the osmolar active compound and
packaging [11].
Composition of PD fluids
Currently, all PD fluids are heat sterilized (Fig. 1). Worldwide,
the most abundantly used mixture has remained largely un-















acidic pH [5.5 – 6.5]
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Fig. 1 Ontology of peritoneal dialysis (PD) fluids: For ~50 years, con-
ventional PD fluids have been based on glucose as the osmotically active
agent and are heat sterilized in single-chamber bags at acidic pH with
selected electrolytes (Na, Ca, Mg, and Cl) and a buffer (lactate), resulting
in glucose degradation product (GDP) production. In the early 1990s,
improved biocompatibility was achieved by introducing multichamber
bags to reduce generation of GDP and allow the use of more physiologic
buffers (such as bicarbonate) and pH. At the same time, alternative agents
were introduced, such as an osmotically active amino acid mixture and
the oncotically active glucose polymer icodextrin
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these single-chamber-bags, glucose levels >10–50× normal
serum levels are heat sterilized together at acidic pH with
selected electrolytes (Na, Ca, Mg, and Cl) and a buffer (lac-
tate). Concentration of the nonphysiological dialysate buffer
lactate is 35-fold above normal serum levels; the
unphysiologically low pH (5.5) is chosen to reduce generation
of highly reactive and cytotoxic GDP and glucose
caramelization [12]. This bioincompatibility has been a matter
of active research for >30 years and has resulted in more
physiological compounding of glucose-based PD fluids in
multihamber bags, in which glucose, electrolytes, and buffer
substances are separately stored and heat sterilized [13]. This
Bsecond generation^ of PD fluids allows use of the physiolog-
ic buffer bicarbonate at supraphysiological concentrations
(34 mmol/l) or at physiological concentration when combined
with lactate. Moreover, the separation of glucose and buffer
substances allows heat sterilization of glucose at extremely
low pH (2–3), resulting in markedly lower—but still biologi-
cally relevant—concentrations of GDP and a markedly higher
pH (8–9) in the buffer compartment, resulting in neutral to
physiological pH of the ready-mixed glucose-based PD fluids
prior to clinical use (pH 7–7.4).
In addition, alternative osmotically (or oncotically) active
agents were introduced in single-chamber bags, such as the
glucose polymer icodextrin and a mixture of amino acids.
Albeit reducing the typical toxicity of glucose (heat steriliza-
tion of icodextrin still results in glucose degradation
byproducts), these novel compounds exhibit nonspecific
(such as low pH) and novel substance-specific bioincom
patible properties. For example, use of icodextrin resulted in
sterile inflammation, most likely due to contamination with
bacterial fragments during the production process [14, 15],
and an increase in serum levels of icodextrin and its degrada-
tion products. Use of amino acids (compounded in PD fluid at
about 10× their physiologic serum levels) resulted in different
specific perturbances of biological functions, such as vascular
effects of arginine [16]. Stable isotope studies in adult contin-
uous ambulatory peritoneal dialysis (CAPD) patients using
once-daily amino acid PD solution together with glucose-
containing fluid demonstrated improved protein anabolism
and a 4% higher protein synthesis rate compared with patients
treated with a glucose-containing PD solution only [17, 18].
According to the International Pediatric Peritoneal Dialysis
Network (IPPN) (www.pedpd.org), only 3 % of PD patients
use amino-acid-containing fluids, presumably due to the limited
anabolic effect and the widespread use of tube feeding.
Low-sodium PD fluids have yielded ambiguous findings in
adult PD patients. Applying dialysate solutions with
<105 mmol/l of sodium resulted in loss of UF, unless the
decline in solution osmolarity was compensated for by glu-
cose [19]. PD fluids with mildly reduced sodium content ap-
plied throughout increased dialytic sodium removal by 50 %
and reduced blood pressure, but this was accompanied by a
decline in residual renal function [20]. Likewise, the concept
of adapted automated PD of combining small, short cycles
followed by long, large cycles without increasing total dialy-
sate fluid exposure per session might have the potential to
improve dialytic sodium removal and blood pressure control
and thus to mitigating cumulative PD-fluid-associated toxicity
[21]. Mechanisms of the speculated enhanced diffusive trans-
port, however, remain elusive and are not readily explained by
the current three-pore model. Suggested benefits need to be
balanced against potential risks, e.g., associated with higher
intraperitoneal pressure during the large dwells, and require
thorough assessment in the pediatric population [22].
Clinical impact of low GDP PD fluids
With regard to actual outcome data obtained in adequate clin-
ical trials, the level of evidence for improved clinical outcome
is still not undisputable in favor of the novel PD fluids. Early
clinical trials demonstrated an improved biocompatibility
based on effluent markers, such as mesothelial cell viability
marker cancer antigen 125 (CA-125) [23, 24], interstitial in-
tegrity markers hyaluronan, procollagen-1-C-terminal pep-
tide, and procollagen-3-N-terminal peptide [25], effluent sur-
rogate marker of angiogenesis, vascular endothelial growth
factor (VEGF), and of inflammation and interleukin (IL) 6
[26]. Effluent IL6 concentrations predict the highly variable
individual peritoneal membrane solute transport function [27].
In a recent Cochrane analysis of clinical benefits of PD solu-
tions, the authors concluded that low GDP fluids do not in-
duce any further harm in PD patients but do not improve the
incidence of infectious complications such as peritonitis or
preserve long-term peritoneal membrane transport function
[28]. Icodextrin solutions improve UF and hydration status.
Initially unexpected, the use of two-chamber bags resulted in
improved and prolonged maintenance of residual renal urine
output and higher residual renal function >12 months of use
[28], possibly due to the reduction of GDP-related renal cyto-
toxicity [29]. However, it can be regarded as a prototype of the
level of evidence-based medicine in PD that the largest (and
likely best) trial failed in its primary outcome parameter,
slowing the rate of glomerular filtration rate (GFR) decline
[30]. However, that trial turned out to provide evidence for a
protective effect with regard to infectious complications by
significantly reducing the incidence of nonpseudomonas
Gram-negative peritonitis episodes and the overall severity
of peritonitis episodes [31]. Based on these findings, cost ef-
fectiveness of low GDP fluid usage has been suggested [32].
Thus, current outcome data in adults still corroborate the no-
tion of the European Pediatric Dialysis Working Group
(EPDWG), published in this journal in 2011, that low GDP
PD fluids should be used whenever possible [11]. This recom-
mendation was based on randomized controlled trials (RCTs)
in adult PD patients [23] and on crossover trials in children
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with low versus high GDP solutions, demonstrating similar
peritoneal solute and water transport kinetics [24], reduced
systemic GDP and advanced glycation end-product load
[33], superior correction of metabolic acidosis, and higher
effluent concentrations of mesothelial cell viability surrogate
marker CA125 with the pure bicarbonate-based, low-GDP
fluid [34]. Since then, some new clinical data have been re-
ported in the pediatric population. A prospective randomized
comparison of low GDP fluids revealed better preservation of
UF capacity with bicarbonate versus lactate buffer [35].
Moreover, prospectively collected data in the IPPN suggests
improved longitudinal growth in infants treated with lowGDP
fluids, potentially due to attenuated local and systemic inflam-
matory and carbonyl stress. This association prevailed even
after correction for nutritional status and region but, however,
does not rule out confounding factors such as specific socio-
economic status and quality of care associated with low and
high GDP fluid usage within the four regions analyzed, and
thus requires randomized controlled trials (RCTs) for verifica-
tion [36].
The impact of lowGDP fluids on preservation of long-term
peritoneal membrane transport function, however, remains
elusive. Small-sized RCTs in adults found no differences in
peritoneal transport capacity with low and high GDP fluids
over time [37, 38], with the exception of UF capacity in the
Euro-Balance trial, in which it declined with pure lactate-
buffered low GDP fluid but was fully compensated for by a
concomitant increase in residual urine production [23]. In the
Balanz trial [39], patients with low GDP fluid usage initially
had significantly higher peritoneal solute transport rates,
which remained stable over the 2-year follow-up period, and
peritoneal UF was lower but increased significantly over time.
Patients receiving conventional PD solutions experienced pro-
gressive increases in peritoneal solute transport rates and sta-
ble peritoneal UF over time. Adequately powered RCTs pri-
marily addressing PD-fluid-induced changes in peritoneal
membrane function over time are warranted.
Compelling evidence for a persistently high degree of
bioincompatibility of low GDP fluids and thus the still great
medical need to improve PD fluids to be used in the pediatric
population is emerging from the International Pediatric
Peritoneal Biopsy Study Group (see Fig. 2). Data from 110
children (85 % on low GDP fluid) obtained in a global effort
and analyzed within the European Training and Research in
Peritoneal Dialysis (EuTRiPD) consortium (www.eutripd.eu)
demonstrate major transformation of the peritoneal membrane
with low GDP fluids, including inflammation, progressive
fibrosis and angiogenesis [40], i.e. alterations as previously
described with high GDP fluids in adults [41], and clearly
exceeding uremia-related alterations reported in adults [42].
Quantitative assessment of the healthy parietal peritoneum
and omentum in >100 individuals revealed marked age-
dependent variations in blood- and lymphatic-vessel density,
and derived reference ranges now provide a framework for
future histomorphometric analyses and peritoneal transport
modeling [43].
Pathomechanisms relevant in PD
PD fluids play a major role in triggering and/or propagating
pathomechanisms that are likely relevant for local and system-
ic complications in PD (see Fig. 3). These complications can
be categorized into local and systemic and into infectious and
noninfectious complications.
Local infectious complications—in particular, peritonitis—
still belong to the most frequent, debilitating, and costly com-
plications of PD [10]. There is a broad body of clinical and
experimental data demonstrating that, in particular, heat-
sterilized glucose-based dialysis fluids are detrimental for
peritoneal host defense [44]. Initial studies focusing on
in vitro exposure of different cells of the peritoneal immune
system to glucose-based, single-chamber-bag, acidic, lactate-
buffered PD fluids provided clear evidence for severe func-
tional impairment and even cell death following more extend-
ed exposure [45]. Earlier studies used unspecific cytotoxicity
assays, whereas later studies increasingly focused on the role
of glucose-related impairment of cells relevant in peritoneal
immune defense [12]. Introduction of the multi-chamber-bag
PD fluids has markedly reduced the level of acute cytotoxic-
ity; still, these PD fluids are heat sterilized and contain glucose
and GDP at concentrations beyond those that were reported in
diabetes patients [46]. Metabolic stress by nonphysiological
high-glucose levels induces cellular signaling systems (also)
involved in immune defense, thereby increasing the risk of
peritoneal infection despite reduced amounts of GDP [47].
Currently marketed alternate osmotic agents also appear to
Fig. 2 Representative section of the peritoneum of a 13.5-year-old girl
on chronic peritoneal dialysis (CPD) devoid of peritonitis. The mesothe-
lial cell layer is still preserved; the submesothelial vessel density [brown
cluster of differentiation (CD31) staining], however, is markedly in-
creased despite low glucose degradation product (GDP) fluid usage.
The three-layer structure of vessels as reported in healthy controls [43]
has disappeared (scale bar = 100 μm)
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result in relatively impaired peritoneal host defense [48].
Thus, intermittent exposure of the immune-compromised
peritoneal cavity with bacterial, viral, or fungal species via
touch contamination or transintestinal migration still frequent-
ly causes subclinical and clinical inflammatory episodes. At
present, peritonitis results in technique failure in 8 % of chil-
dren on PD and in lethal outcome in 1 % [49].
Infectious stimuli together with repeated physicochemical
insults by bioincompatible PD fluids propagate smouldering
inflammation in the peritoneal cavity. Experimental research
in animal and cell culture systems has established a clear role
for IL6 in chronic smouldering inflammation triggered by
infectious stimuli [50]. IL6 is not only associatedwith changes
in peritoneal transport characteristics, likely reflecting perito-
neal remodeling, but also—when measured systemically—
with overall outcome and patient mortality [51]. More recent-
ly, the IL17 system has been identified as a further important
player in peritoneal inflammation [52–54].
The combination of chronic infectious, inflammatory, and
cytotoxic insults—in particular, in the context of a diabetes-
like milieu—results in abnormal peritoneal repair and stress
processes. In particular, regulation of epithelial mesenchymal
transdifferentiation (EMT) has been shown to play a major
role in peritoneal fibrosis and angiogenesis, ultimately
resulting in UF failure in PD [55]. Regarding how far EMT
merely represents a good biomarker by which to monitor PD
patient management, or whether EMT is an independent
pathomechanism that might be amenable for specific interven-
tions, is an ongoing scientific debate [56]. In addition, oxida-
tive stress and senescence are pathomechanisms that likely
mediate glucose-related toxicity, in particular glycation
processes by reactive carbonyl compounds, resulting in ad-
vanced glycosylation end products (AGEs) [57]. Finally, PD
fluids result in abnormal cellular stress responses, with damp-
ening of heat-shock proteins, and increased vulnerability of
peritoneal cell populations and thereby in enhanced chronic
inflammation, peritoneal membrane damage, and hampered
host defense [58–60] .
Ultimately, the above described pathomechanisms might
not be relevant for local infectious and noninfectious compli-
cations only but also for systemic effects, such as further prop-
agating uremia-induced systemic inflammation. Indeed, use
of PD fluids that are more biocompatible has resulted in some
evidence of reduced systemic inflammation [61] and better
maintained residual renal function [28].
Future solutions
Based on the concept that the common denominator for most
pathomechanisms underlying local and systemic complica-
tions of PD is glucose-related toxicity, two PD-fluid-related
work streams to improve PD therapy become obvious: re-
placement of glucose by alternative, biologically inert, but
osmotic active substances; and/or addition of active com-
pounds to counteract glucose-related toxicity.
The main problem in replacing glucose in PD fluids
comes from the massive total daily amount of any such
osmotic compound needed. Provided an average prescrip-
tion of four 2-l bags of 1.5 % glucose-based PD fluid to
an adult patient, the local peritoneal exposure amounts to


















Fig. 3 Combination of bioincompatibility of current peritoneal dialysis
(PD) fluids in combination with infection and chronic inflammation re-
sults in abnormal peritoneal repair processes. Oxidative stress, senes-
cence, and inadequate cellular stress responses are pathomechanisms that
mediate glucose-related toxicity, enhance chronic inflammation, and re-
duce peritoneal host defence, thereby contributing to a vicious circle.
Epithelial mesenchymal transdifferentiation (EMT) further mediates peri-
toneal membrane damage by peritoneal fibrosis and angiogenesis, ulti-
mately resulting in technical failure of PD. These pathomechanisms
might be amenable to therapeutic interventions by specific counteracting
compounds
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absorbed. Replacement of glucose by amino acids is
therefore limited to a single exchange per day due to spe-
cific adverse effects, such as elevation of blood urea ni-
trogen, metabolic acidosis, and uremic symptoms [62].
Absorption of the osmotic agent can only be reduced by
using larger compounds, such as icodextrin, but still re-
sults in potentially relevant systemic loads [63]. Taken
together, the daily absorbed amount of any small/low mo-
lecular weight solute from PD fluid needs careful consid-
eration of eventual systemic intolerability, especially in
this population with virtually nonexistent renal clearance.
Although in experimental PD systems several compounds
with attractive biochemical profiles have been successful-
ly applied to replace glucose, only very few of these were
ultimately tested in PD patients, and none of them has
been approved for clinical use to date. Recently, the
glucose-replacing sweetener, stevioside, has been patented
for PD use. Hyperbranched polyglycerol has experimen-
tally been introduced as a non-glucose-based osmotic
agent in PD fluid and showed promising data in early
animal studies [64]. However, due to the above-
mentioned need to exclude long-term systemic toxicity
of these compounds, administered at doses far above the
naturally occurring exposure levels in the vulnerable PD
population, extensive safety studies are required prior to
their introduction into clinical practice. Therefore, the use
of clinically available alternative solids is currently limit-
ed to icodextrin and an amino acid mix dosed as a single
bag per day.
Due to the relative safety of glucose experienced over
>50 years of intraperitoneal use and its well-known side
effects, an alternative approach is the addition of active
compounds counteracting glucose-related toxicity (see
Fig. 3). The majority of these compounds (as reviewed
in detail in [65] and in [66]) have been selected by a
hypothesis-driven approach. Several of these compounds
are highly specific pharmacologic agents or biologics that
counteract specific pathways identified to be relevant in
PD-related complications. For example, peroxisome
proliferator-activated receptor (PPAR)-gamma agonists,
such as rosiglitazone, have been shown in experimental
PD systems to result in improved membrane integrity and
to reduce inflammation. Addition of bone morphogenic
protein (BMP)-7 mitigates mechanisms such as chronic
inflammation and EMT (reviewed in detail in [65],
[66]). More recently, use of antagomir has proven to ef-
fectively counteract peritoneal fibrosis in a rodent model
of PD [67]. However, similar to the case with complete
replacement of glucose, these specific medications will
need thorough preclinical and clinical testing before the
possibility of their clinical use. According to www.
c l i n i c a l t r i a l s . g ov, o f t h e s e compound s , on l y
glycosaminoglycans such as heparin and low molecular
weight heparinoids have reached the clinical stage but
have not resulted in reproducible clinical benefits (online
search January 2016).
Another promising approach is the addition of nontoxic
agents to PD fluids in doses shown to be safe by prior use as
nutritional supplements in patients with stage 5 chronic kid-
ney disease on dialysis (CKD5D). Historically, several such
compounds were tested in experimental settings but did not
successfully undergo further clinical development
(http://www.uptodate.com/contents/peritoneal-dialysis-
solutions). Of these compounds, only carnitine and alanyl-
glutamine dipeptide are in clinical development. For both
agents, favorable profiles of systemic effects have been previ-
ously reported, such as improved metabolism and immune
competence [68]. In a recent phase II trial in nondiabetic PD
patients, carnitine-enriched PD fluids improved glucose me-
tabolism [69]. Addition of alanyl-glutamine has resulted in
restoration of cellular stress responses, attenuation of perito-
neal inflammation, and protection of the peritoneal membrane
in experimental systems [54, 60] and is being tested in a phase
II trial (EudraCT Number: 2013-000400-42). It certainly re-
mains to be proven in prospective phase III trials whether
novel Bthird-generation PD fluids^ are able to prevent the
complications that currently hamper PD treatment.
Perspectives
A large body of experimental evidence and respective RCTs
have resulted in the introduction of the currently available, so-
called biocompatible, PD fluids, which have yielded certain
clinical benefits such as better preservation of residual renal
function and, in the case of icodextrin, improved fluid control
and blood pressure. However, they still exert considerable
toxicity, and their benefits regarding infectious complications,
PD membrane preservation, cardiovascular health, and patient
survival still need demonstration. PD patient morbidity and
mortality is still unacceptably high in both adult and pediatric
patients, mandating innovative approaches, i.e., PD fluids
with less local and systemic toxicity and, ideally, even actively
counteracting uremic sequelae such as carbonyl and oxidative
stress, as may be the case with specific pharmacologic agents
such as alanyl-glutamine dipeptide. Introduction of various
novel PD fluids with specific local and systemic benefits
should allow for a more personalized treatment of PD patients.
Not all patients may benefit from these more costly PD fluids,
and thus identification of those who will have a particularly
high benefit from the novel therapy or who have a particularly
high risk with the current standard fluids is required. Thus,
development of new PD fluids must go hand-in-hand with the
development of biomarkers to identify patients in need of
these innovative therapies. How far this approach will
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improve overall outcome and QoL of PD patients will be the
topic of future research.
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